Maze Therapeutics director Paula A. Johnson files initial beneficial ownership statement
MAZE•Director files initial Form 3
- Maze Therapeutics director Paula A. Johnson filed an initial Form 3 on Aug. 17, 2026.
Related News
SurgePays delays Q2 10-Q filing after holdup completing financial statements
SURG•
BRC CFO Matthew L. Amigh acquires 10,000 shares for $8,489
BRCC•
Santander Brasil held extraordinary shareholder meeting, remote voting map showed
BSBR•
Advanced Flower Capital CFO, Treasurer Brandon Hetzel acquires 1,463 common shares for $4,389
AFCG•
Google to buy Spirit Airlines business data for $10 million
GOOGL•